Navigation Links
Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
Date:2/26/2009

Findings have implications for treating returning vets and others exposed to laser burns

BOSTON, Feb. 26 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have shown for the first time that a laser burn to one retina can cause both eyes to lose a special protective ability known as immune privilege. Immune privilege protects the eye without the inflammation of the body's normal immune response, which can further damage delicate eye tissue. This finding, published in the February 2009 American Journal of Pathology, has implications for treating patients with laser burns sustained on the battlefield and in other modern settings.

The discovery is also significant because it suggests a previously unknown communication between the two eyes. "This deepens our understanding of the way immune privilege works," says Dr. Joan Stein Streilein, principal investigator of the study and senior scientist at Schepens Eye Research Institute.

Immune privilege is a modification of the body's normal immune response. It protects the eye, the brain and the reproductive system without the full-blown immune response that uses inflammation to violently reject foreign tissue or invaders.

While inflammation in other parts of the body is a useful battle between immune and foreign cells, it is too aggressive for fragile eye, brain and reproductive tissues, and, in the case of the eye, can even lead to blindness. Immune privilege, which intervenes in the battle, is also what prevents the eye from rejecting corneal transplants, making them the most common and successful of transplanted tissues.

In her laboratory, Stein-Streilein and her team made tiny laser burns in one of the retinas of 15 mice. They then injected either the burned or the unburned eyes of each mouse with the antigen, Ovalbumin. Antigens are substances that the body perceives as foreign and against which it mounts a defense.

They found that immune privilege was disrupted in both eyes after six hours and continued to be disrupted even after 56 days.

When they injected the same antigen into the eyes of a group of control mice without burns, they observed no inflammation.

Since created in the 1960s, lasers have found their way onto the battlefield, into the operating rooms and into modern research laboratories. While ophthalmologists have been aware of the local damage done by laser burns to retinas, they have not been tuned into the possibility of long-term loss of immune privilege in one or both eyes.

Understanding mechanisms that destroy or disrupt immune privilege will ultimately lead to novel therapies to restore that special privilege not only in the eye but in the brain and the reproductive system as well, she adds.

The next steps for the team will be to study the novel mechanisms that allow for communication between the injured and non-injured eye.

Other scientists involved in the study include: First author, Hong Qiao, MD, PhD, and second author Kenyatta Lucas, PhD, both scientists at Schepens.

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the nation.


'/>"/>
SOURCE Schepens Eye Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
2. American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment
3. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
4. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
5. DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing
6. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
7. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
8. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
9. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
10. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ - StarFish Medical, ... development firm, announced today that it has merged with ... medical device industrial design and productization organization.  The resulting ... North America with easier east coast ... the design, engineering, regulatory, and manufacturing process. ...
(Date:3/28/2017)... BOSTON , March 28, 2017 /PRNewswire/ ... today announced a partnership with premium news ... allows pharmaceutical companies to extract key insights from ... text mining technology. The Linguamatics I2E ... top 20 global pharmaceutical companies. The Linguamatics-Dow Jones ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 ... the only option for on-premises installation of its Help System for SharePoint was at ... the system into the entire tenant. , The company recently released a modified ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
(Date:3/28/2017)... NEW YORK, NEW YORK (PRWEB) , ... March ... ... their breakthrough development, NTX Technology™, is the first technology to directly address the ... World Health Organization. NTX Technology™ is a patented compound of FDA and TTB ...
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
Breaking Medicine News(10 mins):